Cogent Biosciences to Participate in the LifeSci Partners Immunology and Inflammation Symposium
Cogent Biosciences, a biotechnology company focused on precision therapies for genetically defined diseases, announced management's participation in a fireside chat at the LifeSci Partners Immunology and Inflammation Symposium on May 10, 2022, at 3:30 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cogent Biosciences, a biotechnology company focused on precision therapies for genetically defined diseases, announced management's participation in a fireside chat at the LifeSci Partners Immunology and Inflammation Symposium on May 10, 2022, at 3:30 p.m. ET. The event will be accessible via a live audio webcast on the company's website, with an archived replay available for 30 days. Cogent's lead program, bezuclastinib, targets the KIT D816V mutation and other KIT exon 17 mutations, which are linked to systemic mastocytosis and gastrointestinal stromal tumors (GIST).
Details
News Market Reaction – COGT
The recorded move for COGT in the trading session of this news was -3.69%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass. and BOULDER, Colo., May 06, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that management will participate in a fireside chat at the LifeSci Partners Immunology and Inflammation Symposium on Tuesday, May 10, 2022 at 3:30 p.m. ET.
A live audio webcast will be available through the Investors and Media section of the Cogent website at https://investors.cogentbio.com/events. An archived replay will be available on the Company’s website for 30 days.
About Cogent Biosciences, Inc.
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. In addition to bezuclastinib, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting FGFR2 and ErbB2. Cogent Biosciences is based in Cambridge, MA and Boulder, CO. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: Twitter and LinkedIn. Information that may be important to investors will be routinely posted on our website and Twitter.
Investors:
Christi Waarich
Senior Director, Investor Relations
christi.waarich@cogentbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.